Manikandan Subramanian1, Edward Thorp1, Ira Tabas2. 1. From the Departments of Medicine (M.S., I.T.), Pathology and Cell Biology (I.T.), and Physiology and Cellular Biophysics (I.T.), Columbia University, New York, NY; and Department of Pathology, Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL (E.T.). 2. From the Departments of Medicine (M.S., I.T.), Pathology and Cell Biology (I.T.), and Physiology and Cellular Biophysics (I.T.), Columbia University, New York, NY; and Department of Pathology, Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL (E.T.). iat1@columbia.edu.
Abstract
RATIONALE: Granulocyte macrophage colony-stimulating factor (GM-CSF, Csf2) is a growth factor for myeloid-lineage cells that has been implicated in the pathogenesis of atherosclerosis and other chronic inflammatory diseases. However, the role of GM-CSF in advanced atherosclerotic plaque progression, the process that gives rise to clinically dangerous plaques, is unknown. OBJECTIVE: To understand the role of GM-CSF in advanced atherosclerotic plaque progression. METHODS AND RESULTS: Ldlr(-/-) mice and Csf2(-/-)Ldlr(-/-) mice were fed a Western-type diet for 12 weeks, and then parameters of advanced plaque progression in the aortic root were quantified. Lesions from the GM-CSF-deficient mice showed a substantial decrease in 2 key hallmarks of advanced atherosclerosis, lesional macrophage apoptosis and plaque necrosis, which indicates that GM-CSF promotes plaque progression. Based on a combination of in vitro and in vivo studies, we show that the mechanism involves GM-CSF-mediated production of interleukin-23, which increases apoptosis susceptibility in macrophages by promoting proteasomal degradation of the cell survival protein Bcl-2 (B-cell lymphoma 2) and by increasing oxidative stress. CONCLUSIONS: In low-density lipoprotein-driven atherosclerosis in mice, GM-CSF promotes advanced plaque progression by increasing macrophage apoptosis susceptibility. This action of GM-CSF is mediated by its interleukin-23-inducing activity rather than its role as a growth factor.
RATIONALE: Granulocyte macrophage colony-stimulating factor (GM-CSF, Csf2) is a growth factor for myeloid-lineage cells that has been implicated in the pathogenesis of atherosclerosis and other chronic inflammatory diseases. However, the role of GM-CSF in advanced atherosclerotic plaque progression, the process that gives rise to clinically dangerous plaques, is unknown. OBJECTIVE: To understand the role of GM-CSF in advanced atherosclerotic plaque progression. METHODS AND RESULTS:Ldlr(-/-) mice and Csf2(-/-)Ldlr(-/-) mice were fed a Western-type diet for 12 weeks, and then parameters of advanced plaque progression in the aortic root were quantified. Lesions from the GM-CSF-deficientmice showed a substantial decrease in 2 key hallmarks of advanced atherosclerosis, lesional macrophage apoptosis and plaque necrosis, which indicates that GM-CSF promotes plaque progression. Based on a combination of in vitro and in vivo studies, we show that the mechanism involves GM-CSF-mediated production of interleukin-23, which increases apoptosis susceptibility in macrophages by promoting proteasomal degradation of the cell survival protein Bcl-2 (B-cell lymphoma 2) and by increasing oxidative stress. CONCLUSIONS: In low-density lipoprotein-driven atherosclerosis in mice, GM-CSF promotes advanced plaque progression by increasing macrophage apoptosis susceptibility. This action of GM-CSF is mediated by its interleukin-23-inducing activity rather than its role as a growth factor.
Authors: Tracie A Seimon; Marissa J Nadolski; Xianghai Liao; Jorge Magallon; Matthew Nguyen; Nicole T Feric; Marlys L Koschinsky; Richard Harkewicz; Joseph L Witztum; Sotirios Tsimikas; Douglas Golenbock; Kathryn J Moore; Ira Tabas Journal: Cell Metab Date: 2010-11-03 Impact factor: 27.287
Authors: Andrew J Murphy; Mani Akhtari; Sonia Tolani; Tamara Pagler; Nora Bijl; Chao-Ling Kuo; Mi Wang; Marie Sanson; Sandra Abramowicz; Carrie Welch; Andrea E Bochem; Jan Albert Kuivenhoven; Laurent Yvan-Charvet; Alan R Tall Journal: J Clin Invest Date: 2011-10 Impact factor: 14.808
Authors: Sina Tavakoli; John D Short; Kevin Downs; Huynh Nga Nguyen; Yanlai Lai; Wei Zhang; Paul Jerabek; Beth Goins; Mehran M Sadeghi; Reto Asmis Journal: Radiology Date: 2016-11-16 Impact factor: 11.105
Authors: Aliia R Fatkhullina; Iuliia O Peshkova; Amiran Dzutsev; Turan Aghayev; John A McCulloch; Vishal Thovarai; Jonathan H Badger; Ravi Vats; Prithu Sundd; Hsin-Yao Tang; Andrew V Kossenkov; Stanley L Hazen; Giorgio Trinchieri; Sergei I Grivennikov; Ekaterina K Koltsova Journal: Immunity Date: 2018-10-30 Impact factor: 31.745